Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

974 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Vorwort des DGHO-Vorstandes].
Einsele H, Hochhaus A, de Wit M, Schulz CO. Einsele H, et al. Oncol Res Treat. 2022;45 Suppl 1:5. doi: 10.1159/000525537. Epub 2022 Jul 22. Oncol Res Treat. 2022. PMID: 35871509 Free article. German. No abstract available.
[Vorwort].
Trümper L, Einsele H, de Wit M, Tamm I. Trümper L, et al. Among authors: einsele h. Oncol Res Treat. 2021;44 Suppl 1:1. doi: 10.1159/000517495. Epub 2021 Jul 16. Oncol Res Treat. 2021. PMID: 34344011 Free article. German. No abstract available.
[Klinische Studien in der Hämatologie und Onkologie].
Einsele H, Steutel H, Eichhorst B, Göbeler ME, Hochhaus A, Nickel L, von Messling V, Deggerich A, Nettekoven G. Einsele H, et al. Oncol Res Treat. 2022;45 Suppl 1:6-32. doi: 10.1159/000525371. Epub 2022 Jul 22. Oncol Res Treat. 2022. PMID: 35871514 Free article. German. No abstract available.
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.
Wörmann B, Bokemeyer C, Burmeister T, Köhne CH, Schwab M, Arnold D, Blohmer JU, Borner M, Brucker S, Cascorbi I, Decker T, de Wit M, Dietz A, Einsele H, Eisterer W, Folprecht G, Hilbe W, Hoffmann J, Knauf W, Kunzmann V, Largiadèr CR, Lorenzen S, Lüftner D, Moehler M, Nöthen MM, Pox C, Reinacher-Schick A, Scharl A, Schlegelberger B, Seufferlein T, Sinn M, Stroth M, Tamm I, Trümper L, Wilhelm M, Wöll E, Hofheinz RD. Wörmann B, et al. Among authors: einsele h. Oncol Res Treat. 2020;43(11):628-636. doi: 10.1159/000510258. Epub 2020 Oct 23. Oncol Res Treat. 2020. PMID: 33099551 Free article. Review.
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation.
Kunadt D, Stasik S, Metzeler KH, Röllig C, Schliemann C, Greif PA, Spiekermann K, Rothenberg-Thurley M, Krug U, Braess J, Krämer A, Hochhaus A, Scholl S, Hilgendorf I, Brümmendorf TH, Jost E, Steffen B, Bug G, Einsele H, Görlich D, Sauerland C, Schäfer-Eckart K, Krause SW, Hänel M, Hanoun M, Kaufmann M, Wörmann B, Kramer M, Sockel K, Egger-Heidrich K, Herold T, Ehninger G, Burchert A, Platzbecker U, Berdel WE, Müller-Tidow C, Hiddemann W, Serve H, Stelljes M, Baldus CD, Neubauer A, Schetelig J, Thiede C, Bornhäuser M, Middeke JM, Stölzel F; A. M. L. Cooperative Group (AMLCG), Study Alliance Leukemia (SAL). Kunadt D, et al. Among authors: einsele h. J Hematol Oncol. 2022 Sep 5;15(1):126. doi: 10.1186/s13045-022-01339-8. J Hematol Oncol. 2022. PMID: 36064577 Free PMC article.
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis.
Middeke JM, Teipel R, Röllig C, Stasik S, Zebisch A, Sill H, Kramer M, Scholl S, Hochhaus A, Jost E, Brümmendorf TH, Naumann R, Steffen B, Serve H, Altmann H, Kunzmann V, Einsele H, Parmentier S, Schaich M, Burchert A, Neubauer A, Schliemann C, Berdel WE, Sockel K, Stölzel F, Platzbecker U, Ehninger G, Bornhäuser M, Schetelig J, Thiede C; Study Alliance Leukemia (SAL). Middeke JM, et al. Among authors: einsele h. Leuk Lymphoma. 2021 Jun;62(6):1432-1440. doi: 10.1080/10428194.2020.1864354. Epub 2021 Jan 5. Leuk Lymphoma. 2021. PMID: 33399480
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.
Hanoun M, Ruhnke L, Kramer M, Hanoun C, Schäfer-Eckart K, Steffen B, Sauer T, Krause SW, Schliemann C, Mikesch JH, Kaufmann M, Hänel M, Jost E, Brümmendorf TH, Fransecky L, Kraus S, Einsele H, Niemann D, Neubauer A, Kullmer J, Seggewiss-Bernhard R, Görner M, Held G, Kaiser U, Scholl S, Hochhaus A, Reinhardt HC, Platzbecker U, Baldus CD, Müller-Tidow C, Bornhäuser M, Serve H, Röllig C; Study Alliance Leukemia (SAL). Hanoun M, et al. Among authors: einsele h. J Cancer Res Clin Oncol. 2023 Jul;149(8):4611-4621. doi: 10.1007/s00432-022-04356-9. Epub 2022 Sep 28. J Cancer Res Clin Oncol. 2023. PMID: 36167894 Free PMC article. Clinical Trial.
The European LeukemiaNet: achievements and perspectives.
Hehlmann R, Grimwade D, Simonsson B, Apperley J, Baccarani M, Barbui T, Barosi G, Bassan R, Béné MC, Berger U, Büchner T, Burnett A, Cross NC, de Witte TJ, Döhner H, Dombret H, Einsele H, Engelich G, Foà R, Fonatsch C, Gökbuget N, Gluckman E, Gratwohl A, Guilhot F, Haferlach C, Haferlach T, Hallek M, Hasford J, Hochhaus A, Hoelzer D, Kiladjian JJ, Labar B, Ljungman P, Mansmann U, Niederwieser D, Ossenkoppele G, Ribera JM, Rieder H, Serve H, Schrotz-King P, Sanz MA, Saussele S; European LeukemiaNet. Hehlmann R, et al. Among authors: einsele h. Haematologica. 2011 Jan;96(1):156-62. doi: 10.3324/haematol.2010.032979. Epub 2010 Nov 3. Haematologica. 2011. PMID: 21048032 Free PMC article.
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.
Saussele S, Hehlmann R, Fabarius A, Jeromin S, Proetel U, Rinaldetti S, Kohlbrenner K, Einsele H, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Oppliger Leibundgut E, Heim D, Krause SW, Hofmann WK, Hasford J, Pfirrmann M, Müller MC, Hochhaus A, Lauseker M. Saussele S, et al. Among authors: einsele h. Leukemia. 2018 May;32(5):1222-1228. doi: 10.1038/s41375-018-0055-7. Epub 2018 Feb 26. Leukemia. 2018. PMID: 29479070 Free PMC article. Clinical Trial.
Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia.
Eckardt JN, Stasik S, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Stölzel F, Kroschinsky F, Schetelig J, Bornhäuser M, Thiede C, Middeke JM. Eckardt JN, et al. Among authors: einsele h. Cancers (Basel). 2021 Apr 26;13(9):2095. doi: 10.3390/cancers13092095. Cancers (Basel). 2021. PMID: 33926021 Free PMC article.
974 results